Use of Noninvasive Biomarker Tests vs. FibroScan for Predicting Significant Fibrosis in Egyptian Pediatric Cancer Survivors with Chronic Hepatitis C Virus Infection Authors: Dalia N Toaima, Fatma A Marzouk, Alaa El-Haddad, Aisha Elsharkawy, Gamal E Esmat, Manal H El-Sayed Published: 2026 ABSTRACT AbstractEgyptian children undergoing chemotherapy are at high risk of hepatitis C virus (HCV) infection because of immunosuppression and multiple blood transfusions. This study evaluated liver fibrosis by comparing transient elastography with aminotransferase-to-platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4) in pediatric cancer survivors with chronic HCV infection. Fifty-one cancer survivors with chronic HCV infection (median age, 13.5 years) were prospectively recruited from the pediatric oncology and hepatology clinics at Ain Shams University and the National Cancer Institute. All participants underwent noninvasive fibrosis assessment using transient elastography, APRI, and FIB-4, as well as liver function testing, ultrasonography, and liver biopsy when necessary. Based on liver stiffness measurements, patients were classified into group 1 (fibrosis stage F0–F2; 80.4%) or group 2 (fibrosis stage F3–F4; 19.6%). Compared with group 1, group 2 had significantly higher serum bilirubin and alanine aminotransferase (ALT) levels, lower platelet counts, and higher APRI and FIB-4 scores (p<0.05). Liver stiffness was positively correlated with APRI, FIB-4, chemotherapy duration, ALT, ALP, and ferritin (p<0.05). The AUROCs of APRI and FIB-4 for predicting significant fibrosis (F3–F4) were 0.85 and 0.712, respectively. The cutoff values providing the best prediction of mild and severe fibrosis were 0.86 for APRI and 0.52 for FIB-4. APRI was more accurate than FIB-4 for detecting significant fibrosis. In conclusion, APRI and FIB-4 are useful noninvasive alternatives for assessing hepatic fibrosis in resource-limited countries, with APRI being preferable to FIB-4 for detecting significant fibrosis.Keywords: Hepatitis C, Cancer survivors, Elastography, Liver stiffness, Aspartate aminotrans-ferase-to-platelet-ratio index, Fibrosis index based on four factors INTRODUCTION Survivors of childhood malignancies in Egypt are at high risk of hepatitis C virus (HCV) infection because of immunosuppression and the multiple blood transfusions required during chemotherapy. If left untreated, chronic HCV infection can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [1]. Assessing the degree of hepatic fibrosis is essential when determining antiviral therapy for chronic HCV infection [2]. Although liver biopsy remains a reliable method for assessing hepatic fibrosis, it is invasive, causes pain and discomfort, and may result in rare but non-negligible complications, such as sepsis, bleeding, and damage to surrounding structures [3,4]. In addition, histopathologic examination is subject to interobserver and intraobserver variability; therefore, liver biopsy has largely been replaced by noninvasive methods for staging liver fibrosis in chronic hepatitis C (CHC) [5]. Transient elastography (TE) has several desirable features as a noninvasive tool for staging liver fibrosis: it is inexpensive, accurate, reproducible, and operator-independent, with reported sensitivity and specificity of 87% and 91%, respectively, for detecting liver cirrhosis in patients with CHC infection [6]. Noninvasive methods can reliably differentiate minimal from significant fibrosis, thereby avoiding liver biopsy in a substantial proportion of patients [7]. Several noninvasive biomarker tests, including the aspartate aminotransferase-to-platelet ratio index (APRI), the fibrosis index based on four factors (FIB-4) [8], the Forns index, FibroIndex, FibroTest, FibroMeter, and HepaScore, have been developed to predict hepatic fibrosis [7,9,10]. The diagnostic accuracy and optimal cutoff values of APRI and FIB-4 compared with FibroScan have not been well established in patients with CHC, particularly in the pediatric population. Direct-acting antivirals now make it possible to treat patients with CHC. Determining the presence of advanced fibrosis and cirrhosis is important not only for establishing treatment duration but also for guiding further evaluation, follow-up, and HCC surveillance [11]. This prospective study aimed to evaluate liver stiffness measured by transient elastography and compare it with APRI and FIB-4 (which are calculated from AST and platelet count, with FIB-4 additionally incorporating age and alanine aminotransferase [ALT]) for diagnosing advanced fibrosis in pediatric cancer survivors with chronic HCV infection. MATERIALS AND METHODS Participants Fifty-one cancer survivors with chronic HCV infection (mean age, 13.41±4.14 years; range, 4–19 years; 76.5% male) were prospectively recruited from the pediatric oncology clinic at Ain Shams University and the pediatric hepatology clinic at the National Cancer Institute in Cairo, Egypt. The inclusion criteria were HCV RNA positivity, receipt of chemotherapy for a hematologic malignancy, completion of chemotherapy at least 6 months before the study, and compensated liver disease. Patients with decompensated liver disease, concomitant positivity for hepatitis B surface antigen, or ongoing antiviral therapy for HCV infection were excluded. Liver decompensation was defined as the presence of signs of liver failure and/or portal hypertension, such as jaundice, ascites, variceal bleeding, or hepatic encephalopathy. Convenience sampling was used; all eligible patients who attended the pediatric oncology clinic at Ain Shams University or the pediatric hepatology clinic at the National Cancer Institute during the study period and met the inclusion criteria were consecutively recruited. This approach facilitated the efficient enrollment of accessible participants within the clinical setting. The study population included 32 patients (62.7%) with acute lymphoblastic leukemia (ALL), 10 (19.6%) with non-Hodgkin lymphoma (NHL), 6 (11.8%) with Hodgkin disease (HD), and 3 (5.9%) with acute myeloid leukemia (AML). Sample size calculation Based on the results of Rungta et al. [12], which reported an area under the curve (AUC) of 70% for FIB-4, and assuming an AUC of 85% in our study, an alpha error of 5%, and a study power of 80%, the required sample size was 51 patients. The sample size was calculated using Stata, version 10 (StataCorp LP). Ethical considerations The study protocol was approved by the Research Ethics Committee of the Faculty of Medicine, Ain Shams University, and the study was conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from the parents or legal guardians of all study participants. Informed assent was also obtained from children older than 9 years and from adolescents before enrollment in the study. Study procedures A standardized questionnaire was completed for each patient and included medical history data, with an emphasis on transfusion history and hepatitis-related flares, as well as findings from a detailed clinical examination. Hepatitis-related flares were defined as intermittent elevations in aminotransferase activity to more than three times the upper limit of normal and more than twice the baseline value [13]. Laboratory investigations included the following: (a) a complete blood count; (b) liver function tests, including serum ALT and aspartate aminotransferase (AST) levels (laboratory upper limits of normal: 49 IU/L for ALT and 48 IU/L for AST), serum alkaline phosphatase (normal range, 120–360 IU/L), total and direct serum bilirubin, prothrombin time, international normalized ratio (INR), serum ferritin, and serum albumin; (c) viral marker testing for serum HCV antibodies using a third-generation enzyme-linked immunosorbent assay (ELISA; Murex anti-HCV kit, version 4.0; DiaSorin South Africa (Pty) Ltd.) and for serum hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (HBcAb) using ELISA (DiaSorin sAgEIA; DiaSorin S.p.A.); and (d) polymerase chain reaction (PCR) testing for serum HCV RNA using the COBAS AmpliPrep/COBAS TaqMan system. Radiologic investigations (a) Abdominal ultrasonography was performed using a Toshiba 250 ultrasound system with 3.5/5.0-MHz convex probes to examine the liver and spleen. (b) FibroScan was used to measure liver stiffness. Measurements were obtained from the right hepatic lobe through the intercostal spaces, with the patient in the dorsal decubitus position and the right arm in maximal abduction. The transducer probe was placed on the skin between the ribs at the level of the right hepatic lobe. Using time-motion ultrasonographic guidance, the operator identified a liver segment at least 6 cm thick and free of large vascular structures. The measurement depth ranged from 25 to 65 mm. Ten successful measurements were obtained for each patient, and the results were expressed in kilopascals (kPa). The median value was considered representative of the liver elastic modulus. Only procedures with 10 successful measurements were considered reliable [14]. The FibroScan cutoff values were determined according to the METAVIR scoring system [15]. Biochemical markers: APRI and FIB-4 1. Calculation of APRI APRI was calculated using serum AST activity and platelet count according to the formula proposed by Wai et al. [16] in 2003: [(sample AST/reference AST [upper limit of normal])×100]/platelet count. 2. Calculation of FIB-4 (age×AST)/(platelet count×square root of ALT). Liver biopsy Seven patients had persistently elevated liver enzyme levels 1 year after completing chemotherapy and underwent liver biopsy. Ultrasound-guided liver biopsy was performed, and the histopathologic findings were evaluated using the Ishak and METAVIR fibrosis scores [17]. Statistical analysis Data were reviewed, coded, and entered into a computer using the IBM SPSS Statistics for Windows, Version 24.0 (IBM Co). Quantitative data were expressed as the mean±standard deviation or the median and interquartile range for nonparametric data, whereas qualitative data were presented as numbers and percentages. The Student’s t-test or Mann-Whitney U-test was used to compare continuous variables between two groups. The correlation coefficient (r) was used to measure the strength of the linear association between two variables, where r=1 indicates a perfect positive correlation and r=−1 indicates a perfect negative correlation. McNemar’s test was used to compare the two diagnostic tests (biopsy and FibroScan). The diagnostic performance of APRI and FIB-4 was evaluated using the area under the receiver operating characteristic (AUROC) curve. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated to assess the ability of APRI and FIB-4 to detect significant fibrosis. Statistical significance was defined as p<0.05. RESULTS Patients were divided into two groups according to the fibrosis stage determined by transient elastography. Group 1 included patients with fibrosis stages F0–F2 (no significant fibrosis; TE score <9.5 kPa; 80.4%), whereas group 2 included patients with fibrosis stages F3–F4 (TE score ≥9.5 kPa; 19.6%). Patients were classified according to malignancy type as having ALL, NHL, HD, or AML. These groups included 32 (62.7%), 10 (19.6%), 6 (11.8%), and 3 (5.9%) patients, respectively. Seventeen patients (33.3%) were treated with methotrexate (MXT), 28 (54.9%) with MXT and 6-mercaptopurine (6MP), and 6 (11.8%) with other chemotherapy regimens. During chemotherapy, 33 patients (64.7%) experienced fewer than 5 ALT flares, 5 (9.8%) experienced 5–10 flares, and 13 (25.5%) experienced more than 10 flares. Twenty-six patients (51%) received fewer than 5 transfusions, 14 (27.5%) received 5–10 transfusions, and 11 (21.6%) received more than 10 transfusions. Group 2 had a significantly longer duration of chemotherapy and significantly higher serum bilirubin levels, liver stiffness measured by FibroScan, and APRI scores (p<0.001), as shown in Table 1. In addition, group 2 had higher FIB-4 scores, ALT and AST levels, and lower platelet counts (p<0.003, 0.01, 0.001, and 0.01, respectively). The other parameters were comparable between the groups (Table 1). Table 1Comparison of quantitative variables between patients with no or mild fibrosis and patients with severe fibrosisVariableGroup 1 F0–2 (n=41)Group 2 F3–4 (n=10) p-valueAge* (yr)13.22±4.3814.2±3.010.510Weight* (kg)42.19±18.2749.5±21.390.270Height* (cm)142.26±21.07147.90±12.710.420Hb* (g/dL)13.10±1.4013.26±1.230.750WBCs* (103/mm3)6.25±2.006.57±3.970.710Duration of chemotherapy† (mo)35 (11–39)42.5 (38–48)0.001§ Duration of HCV infection† (mo)12 (3–50)12 (3–24)0.704Platelets* (103/mm3)251.36±82.34178.7±59.050.010‡ Total bilirubin† (mg/dL)0.4 (0.2–0.5)0.6 (0.5–0.7)0.001§ Albumin* (g/dL)4.192±0.563.82±0.590.070PT* (s)12.53±0.6412.74±0.920.400ALT† (IU/L)41 (29–72)70.5 (61–79)0.010‡ AST† (IU/L)39 (32–65)68 (61–118)0.001§ ALP* (IU/L)205 (136–249)236 (211–274)0.070Ferritin† (mg/L)66 (44–144)186.5 (50–615)0.085Liver stiffness* (kPa)5.64±1.6713.00±3.660.001§ APRI† 0.48 (0.3–0.7)1.19 (0.89–1.94)0.001§ FIB-4† 0.4 (0.27–0.5)0.72 (0.53–1.04)0.003‡ Values are presented as mean±standard deviation or median (interquartile range).Hb: hemoglobin, WBC: white blood cell, HCV: hepatitis C virus, PT: prothrombin time, ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, APRI: aspartate aminotransferase-to-platelet ratio index, FIB-4: fibrosis-4 index.*Student’s t-test.†Mann-Whitney U-test.‡p<0.05, §p<0.01. Comparison of quantitative variables between patients with no or mild fibrosis and patients with severe fibrosis Values are presented as mean±standard deviation or median (interquartile range). Hb: hemoglobin, WBC: white blood cell, HCV: hepatitis C virus, PT: prothrombin time, ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, APRI: aspartate aminotransferase-to-platelet ratio index, FIB-4: fibrosis-4 index. *Student’s t-test. †Mann-Whitney U-test. ‡p<0.05, §p<0.01. No significant differences were observed between the F0–F2 and F3–F4 groups in sex, chemotherapy type, number of ALT flares during chemotherapy, or number of transfusions. When patients were classified by sex, males had significantly higher hemoglobin levels, ALT and AST levels, liver stiffness measured by transient elastography, and APRI and FIB-4 scores, whereas females had significantly higher platelet counts (Table 2). Table 2Comparison of quantitative variables by sexVariableMale (n=39)Female (n=12) p-valueAge* (yr)13.46±4.2313.25±4.00.870Weight* (kg)42.66±18.6346.75±20.330.510Height* (cm)142.51±21.17146.16±14.500.580Hb* (g/dL)13.40±1.3912.27±0.810.000§ WBCs* (103/mm3)6.13±2.546.90±2.150.340Duration of chemotherapy† (mo)36 (17–42)26.5 (9.5–39.5)0.276Duration of HCV infection† (mo)10 (2–25)21 (8–52)0.136Platelets* (103/mm3)221.38±71.86288.25±99.000.010‡ Total bilirubin+ (mg/dL)0.4 (0.3–0.6)0.35 (0.25–0.5)0.229Albumin* (g/dL)4.09±0.644.20±0.350.470PT* (s)12.57±0.6812.60±0.760.880ALT† (IU/L)62 (32–84)33.5 (19.5–44.5)0.007‡ AST† (IU/L)60 (34–76)33.5 (29.5–39.5)0.043‡ ALP† (IU/L)221 (136–276)173 (143–218)0.123Ferritin† (mg/L)71 (50–230)60.5 (26.5–155)0.230Stiffness* (kPa)7.31±3.996.36±2.20<0.001APRI† 0.61 (0.43–1.03)0.28 (0.22–0.58)0.007§ FIB-4†0.43 (0.3–0.630.31 (0.21–0.48)0.020‡ Values are presented as mean±standard deviation or median (interquartile range).Hb: hemoglobin, WBC: white blood cell, HCV: hepatitis C virus, PT: prothrombin time, ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, APRI: aspartate aminotransferase-to-platelet ratio index, FIB-4: fibrosis-4 index.*Student’s t-test.†Mann-Whitney U-test.‡p<0.05, §p<0.01. Comparison of quantitative variables by sex Values are presented as mean±standard deviation or median (interquartile range). Hb: hemoglobin, WBC: white blood cell, HCV: hepatitis C virus, PT: prothrombin time, ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, APRI: aspartate aminotransferase-to-platelet ratio index, FIB-4: fibrosis-4 index. *Student’s t-test. †Mann-Whitney U-test. ‡p<0.05, §p<0.01. Liver stiffness was positively correlated with APRI, FIB-4, chemotherapy duration, height, ALT, ALP, and ferritin (p<0.05 for all), as shown in Table 3 and Figs. 1 and 2. APRI was positively correlated with total bilirubin, ALT, AST, ferritin, liver stiffness measured by FibroScan, and FIB-4 (p<0.001, 0.001, 0.001, 0.02, and 0.001, respectively), whereas FIB-4 was positively correlated with age, chemotherapy duration, height, hemoglobin, total bilirubin, ALT, AST, ferritin, liver stiffness measured by FibroScan, and APRI (p≤0.05 for all). Table 3Correlations of clinical and laboratory parameters with liver stiffness measured by FibroScanParameterr p-valueAge (yr)0.220.11Weight* (kg)0.28* 0.04Height* (cm)0.31* 0.02Duration of chemotherapy† (mo)0.37† <0.001Duration of HCV infection (mo)–0.130.34Hb (g/dL)0.2130.13WBCs (103/mm3)–0.0180.90Platelets (103/mm3)–0.250.06Total bilirubin (mg/dL)0.220.11Albumin (g/dL)–0.200.14PT (s)0.100.47ALT (IU/L)0.280.04AST (IU/L)0.250.06ALP† (IU/L)0.45† <0.001Ferritin† (mg/L)0.52† <0.001APRI* 0.32* 0.02FIB-4† 0.40† <0.001r: correlation coefficient, HCV: hepatitis C virus, Hb: hemoglobin, WBC: white blood cell, PT: prothrombin time, ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, APRI: aspartate aminotransferase-to-platelet ratio index, FIB-4: fibrosis-4 index.*Correlation is significant at the 0.05 level.†Correlation is significant at the 0.01 level. Correlations of clinical and laboratory parameters with liver stiffness measured by FibroScan r: correlation coefficient, HCV: hepatitis C virus, Hb: hemoglobin, WBC: white blood cell, PT: prothrombin time, ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, APRI: aspartate aminotransferase-to-platelet ratio index, FIB-4: fibrosis-4 index. *Correlation is significant at the 0.05 level. †Correlation is significant at the 0.01 level. Correlation between APRI and liver stiffness measured by FibroScan. APRI: aspartate aminotransferase-to-platelet ratio index. Correlation between FIB-4 and liver stiffness measured by FibroScan. FIB-4: fibrosis-4 index. The AUROCs of APRI and FIB-4 for predicting significant fibrosis (F3–F4) were 0.85 (95% confidence interval [CI], 0.720–0.992) and 0.712 (95% CI, 0.503–0.921), respectively (Fig. 3). ROC curves for APRI and FIB-4 in predicting severe fibrosis. APRI: aspartate aminotransferase-to-platelet ratio index, FIB-4: fibrosis-4 index, ROC: receiver operating characteristic. For APRI, a cutoff value of 0.86 provided the best prediction of mild and severe fibrosis, with a sensitivity of 80%, specificity of 90.2%, positive predictive value (PPV) of 66.7%, and negative predictive value (NPV) of 94.9. The optimal predictive cutoff value for FIB-4 was 0.52 (sensitivity, 70%; specificity, 85.4%; PPV, 53.8%; and NPV, 92.1%), as shown in Table 4. APRI was more accurate than FIB-4 for detecting significant fibrosis. Table 4Diagnostic accuracy of APRI and FIB-4 relative to FibroScan for predicting significant fibrosis (F3–F4)ParameterTotal (n)F0–2 (n=41)F3–4 (n=10)SensitivitySpecificityPPVNPVAPRI<0.863937280%90.2%66.7%94.9%≥0.861248FIB-4<0.523835370%85.4%53.8%92.1%≥0.521367APRI: aspartate aminotransferase-to-platelet ratio index, FIB-4: fibrosis-4 index, PPV: positive predictive value, NPV: negative predictive value. Diagnostic accuracy of APRI and FIB-4 relative to FibroScan for predicting significant fibrosis (F3–F4) APRI: aspartate aminotransferase-to-platelet ratio index, FIB-4: fibrosis-4 index, PPV: positive predictive value, NPV: negative predictive value. Seven patients underwent ultrasound-guided liver biopsy: 6 (85.7%) had ALL, and 1 (14.3%) had HD. Two patients (28.6%) received methotrexate, 4 (57.1%) received MXT and 6MP, and 1 received another chemotherapy regimen. Three patients (42.9%) experienced more than 10 ALT flares during chemotherapy, 1 (14.3%) experienced 5–10 flares, and 3 experienced fewer than 5 flares. Three patients (42.9%) received fewer than 5 blood transfusions, 1 received more than 5 but fewer than 10 transfusions, and 3 received more than 10 transfusions. Their liver stiffness grades were distributed across the FibroScan scores. According to McNemar’s test, no significant difference was observed between biopsy and FibroScan classifications among the seven patients who underwent liver biopsy; the two tests yielded nearly similar results. Of the patients with METAVIR stage F0–F2 on biopsy, 80% were classified as F0–F2 by FibroScan (4 of 5 patients), whereas 100% of those with METAVIR stage F3–F4 on biopsy were classified as F3–F4 by FibroScan (2 of 2 patients). APRI and FIB-4 scores were consistent with the FibroScan results: the scores were markedly elevated in the two patients classified as F3–F4 by biopsy and in the single patient classified as F3–F4 by FibroScan but as F0–F2 by biopsy. APRI and FIB-4 scores were considerably lower in the other four patients classified as F0–F2. DISCUSSION Despite the favorable prognosis of HCV infection in children during the first two decades of life, approximately 4% to 6% of children show evidence of advanced liver fibrosis or cirrhosis due to progressive HCV infection [18]. Children with chronic HCV infection who undergo chemotherapy have a higher risk of liver disease progression because of multiple factors, including HCV flares and reactivation during chemotherapy, drug toxicity, immunosuppression, and coinfection with hepatitis B virus or human immunodeficiency virus [19,20,21]. In the past, liver biopsy was the only method available for evaluating hepatic fibrosis. However, it is an invasive and painful procedure that carries a risk of life-threatening complications. These limitations have led to the development of noninvasive tools for assessing fibrosis, including biochemical markers and various imaging techniques [22]. It is therefore essential to explore the use of noninvasive tools to assess and monitor liver disease progression in this particularly vulnerable population. Several studies have shown that TE accurately predicts hepatic fibrosis in patients with chronic liver disease [7,23]. This prospective study aimed to evaluate liver stiffness measured by FibroScan and compare transient elastography with APRI and FIB-4 for diagnosing advanced fibrosis in pediatric cancer survivors with chronic HCV infection. In the current study, both transaminase levels were elevated. Patients with HCV infection and hematologic malignancies have been reported to experience transient and persistent transaminitis during chemotherapy [19]. Studies have shown that elevations in liver enzyme levels in children undergoing treatment for ALL may be primarily attributable to hepatitis viruses [24]. However, maintenance therapy with known hepatotoxic drugs may have additional deleterious effects. Patients in the current study experienced ALT flares at varying frequencies during chemotherapy. One study reported that HCV infection is not always benign during childhood and that ALT levels remained elevated in half of the children studied [25]. The higher liver enzyme levels in our study may be explained by the recruitment of patients with postmalignancy HCV infection from the pediatric hepatology clinic after cancer chemotherapy had been withheld, unlike other studies [25,26], in which patients were recruited from pediatric oncology departments and evaluated for the prevalence of HCV infection. In addition, the frequency of ALT flares did not differ significantly between the two patient groups. In the current study, FibroScan results showed negative correlation with platelet count; however, this correlation did not reach statistical significance (p=0.06). Similar negative correlations have been reported in other studies [14,27]. This finding may be explained by the effects of HCV on the bone marrow, platelet precursors, and thrombopoietin. Autoimmune platelet destruction may also occur in patients with active disease [28]. In addition, platelet counts differed significantly between the two groups and were higher in group 1 (p=0.01). Our study showed positive correlations between liver stiffness measured by FibroScan and ALT, ALP, ferritin, APRI, and FIB-4, but no significant correlation between liver stiffness and AST, unlike the findings of other studies [29]. The relationship between serum ALT levels and liver disease progression remains controversial. Some studies have found that greater elevations in ALT and AST levels are the strongest predictors of more rapid fibrosis progression [30]. This association may be related to hepatocyte injury and ALT release. In addition, advanced liver disease may be associated with mitochondrial injury, resulting in greater AST release because AST is present in both the mitochondria and cytoplasm [31]. The median APRI score in patients with mild or no fibrosis was 0.48 (0.3–0.7), and the median FIB-4 score was 0.40 (0.27–0.5). In patients with severe fibrosis or cirrhosis, the median APRI and FIB-4 scores were 1.19 (0.89–1.94) and 0.72 (0.53–1.04), respectively. APRI and FIB-4 differed significantly between patients with mild or no fibrosis and those with severe fibrosis or cirrhosis (p<0.05). Similar findings have been reported in other studies, in which the mean APRI and FIB-4 scores were 0.94±1.2 (median, 0.6) and 1.67±2.80 (median, 1.09), respectively, in the mild fibrosis group and 2.56±2.7 (median, 1.95) and 5.53±5.20 (median, 3.70), respectively, in the advanced fibrosis group; these differences were significant (p<0.0001) [12]. In our study, liver stiffness measured by transient elastography was significantly correlated with APRI and FIB-4, consistent with previous studies [12,32]. We evaluated the diagnostic value of APRI and FIB-4 for predicting significant fibrosis and cirrhosis in our CHC cohort using readily available blood tests. In our study, the AUROC for APRI was higher than that for FIB-4 for predicting significant fibrosis (0.85 vs. 0.712, respectively), whereas another study reported higher AUC values for FIB-4 than for APRI (0.881 and 0.835, respectively) [12]. For APRI, a cutoff value of 0.86 provided the best prediction of mild and severe fibrosis, with a sensitivity of 80%, specificity of 90.2%, PPV of 66.7%, and NPV of 94.9%. For FIB-4, a cutoff value of 0.52 provided the best prediction of mild and severe fibrosis, with a sensitivity of 70%, specificity of 85.4%, PPV of 53.8%, and NPV of 92.1%. Therefore, both tests performed well in predicting significant fibrosis and cirrhosis, although their NPV and PPV differed. APRI was slightly superior to FIB-4 for predicting significant fibrosis, with higher PPV, NPV, sensitivity, and specificity. Our findings are consistent with studies reporting a higher NPV than PPV for predicting or excluding significant fibrosis [33], but differ from studies showing that FIB-4 is superior to APRI for distinguishing patients with and without cirrhosis in the setting of chronic HCV infection [34]. It should be noted that FIB-4 was originally developed in patients coinfected with HCV and HIV, in whom ALT levels are known to be lower than those in patients with HCV monoinfection [35]. Therefore, higher ALT levels may result in lower FIB-4 scores in patients with HCV monoinfection. FIB-4 incorporates patient age and ALT level, whereas APRI does not, resulting in different findings with the predefined cutoff values. The diagnostic accuracies of FIB-4 and APRI in the current study were comparable to those of sonoelastography methods. Although APRI appeared to be more stringent than FIB-4, the clinical relevance of this finding is uncertain. Both FIB-4 and APRI have been shown to have the highest positive predictive values only for the most severe stages of liver fibrosis [36]. APRI has been shown to be superior to FIB-4, consistent with the findings of other studies [37]. One limitation of our study was the lack of liver biopsy data, except for seven patients who were eligible for antiviral therapy and had different METAVIR stages and FibroScan scores. Comparison of patients with mild or no fibrosis and those with severe fibrosis or cirrhosis showed no significant difference between biopsy and transient elastography; the two tests yielded nearly similar results that were consistent with the APRI and FIB-4 scores. Finally, the 2018 World Health Organisation guidelines indicated that the Guidelines Development Group considered APRI and FIB-4 more suitable for resource-limited settings than more expensive options, such as transient elastography [38]. However, when transient elastography is available and its cost is not a barrier, it is also recommended for monitoring liver disease progression in patients with HCV infection. In conclusion, the results indicate that liver stiffness measurement by transient elastography is useful for determining the stage of hepatic fibrosis in pediatric cancer survivors with chronic HCV infection. APRI and FIB-4 are convenient noninvasive alternatives for assessing hepatic fibrosis in resource-limited countries and provide good diagnostic accuracy. APRI showed numerically better diagnostic performance than FIB4 for detecting significant fibrosis. Despite the simplicity and accuracy of APRI, no single cutoff value could be defined to differentiate significant fibrosis from cirrhosis. Larger studies are warranted to confirm the diagnostic accuracy of APRI and FIB-4 and establish cutoff scores appropriate for pediatric populations. Footnotes Funding: None. Conflict of Interest: The authors have no financial conflicts of interest. References